Polycystic ovary syndrome

Norman, Robert J.; Dewailly, Didier; Legro, Richard S.; Hickey, Theresa E.

doi:10.1016/s0140-6736(07)61345-2

Cited by 1,345 publications

(1,067 citation statements)

References 179 publications

Supporting

Mentioning

1,000

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, overweight women experience more menstrual cycle abnormalities, anovulation and infertility than do their normal-weight counterparts 19,20 . Polycystic ovary syndrome (PCOS) is a well-recognized condition affecting fertility in many women, and approximately 50% of PCOS patients have BMI consistent with obesity 21 . The results of our study could be influenced by the fact that obese women could be more likely to have a prolonged menstruation-conception interval.…”

Section: Discussionmentioning

confidence: 99%

Maternal obesity is a potential source of error in mid‐trimester ultrasound estimation of gestational age

Simić

Wahlin

Maršál

et al. 2009

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Maternal obesity is a potential source of error in mid‐trimester ultrasound estimation of gestational age

Simić

Wahlin

Maršál

et al. 2009

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

“…27 These categories are useful in clinical practice because health risks have been defined for at least two subtypes, and this dictates careful evaluation of metabolic disturbances for women with frank or classic PCOS. 27 However, in research settings, subdividing PCOS into more discrete categories is imperative if we are to clearly define incidence, degree of symptomology and health risks among all variants of PCOS (Table 3).…”

Section: Elucidating the Phenotypic Spectrum Of Polycystic Ovary Syndmentioning

confidence: 99%

Diagnostic Criteria for Polycystic Ovary Syndrome: Pitfalls and Controversies

Lujan

Chizen

Pierson

2008

Journal of Obstetrics and Gynaecology Canada

148

View full text Add to dashboard Cite

It is estimated that as many as 1.4 million Canadian women may be afflicted with polycystic ovary syndrome (PCOS). Although PCOS is heralded as one of the most common endocrine disorders occurring in women, its diagnosis, management, and associated long-term health risks remain controversial. Historically, the combination of androgen excess and anovulation has been considered the hallmark of PCOS. To date, while these symptoms remain the most prevalent among PCOS patients, neither is considered an absolute requisite for the syndrome. Inclusion of ultrasonographic evidence of polycystic ovaries as a diagnostic marker has substantially broadened the phenotypic spectrum of PCOS, yet much debate surrounds the validity of these newly identified milder variants of the syndrome. Difficulty in resolving the spectrum of PCOS stems from the continued use of inconsistent and inaccurate methods of evaluating androgen excess, anovulation, and polycystic ovaries on ultrasound. At present, there is no clear-cut definition of biochemical hyperandrogenemia, particularly since we depend on poor laboratory standards for measuring androgens in women. Clinical signs of hyperandrogenism are ill-defined in women with PCOS, and the diagnosis of both hirsutism and polycystic ovarian morphology remains alarmingly subjective. Lastly, there is an inappropriate tendency to assign ovulatory status solely on the basis of menstrual cycle history or poorly timed endocrine measurements. In this review, we elaborate on these limitations and propose possible resolutions for clinical and research settings. By stimulating awareness of these limitations, we hope to generate a dialogue aimed at solidifying the evaluation of PCOS in Canadian women.

show abstract

“…PCOS is the most frequent cause of anovulatory infertility and hyperandrogenism in young women [4]. Women with this syndrome are characterized by an excessive number of small antral follicles (2-3 fold that of normal ovaries) [5].…”

Section: Introductionmentioning

confidence: 99%

“…AMH has therefore been proposed as a novel clinical marker of ovarian reserve [1]. Another major reason for the interest in AMH is the fact that serum AMH levels are increased significantly in women with polycystic ovary syndrome (PCOS) when compared with normoovulatory women [2,3].PCOS is the most frequent cause of anovulatory infertility and hyperandrogenism in young women [4]. Women with this syndrome are characterized by an excessive number of small antral follicles (2-3 fold that of normal ovaries) [5].…”

mentioning

confidence: 99%

Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients

Wei

Gong

2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To investigate whether serum Anti-Müllerian hormone (AMH) on day 3 could predict controlled ovarian stimulation and reproductive outcomes in women with polycystic ovary syndrome. Methods A total of 164 PCOS patients undergoing their first IVF treatment cycle were prospectively included. Serum AMH levels on cycle day 3 was measured. The controlled ovarian stimulation and clinical outcomes for the study population were divided according to the <25th, 25 to 75th, or >75th percentile of serum day-3 AMH. Results Estradiol levels on hCG day and the number of retrieved oocytes significantly increased with increasing serum AMH levels, while total consumption of gonadotropin dose showed a significant decrease (P<0.05). Fertilization rate and the number of good quality embryos were comparable among the low, average and high groups (P>0.05). Embryo implantation rates in the high AMH group was significantly inferior to those with low and average AMH concentration (27 versus 48.8 and 50%, P<0.01). Clinical pregnancy rates was lower in the high AMH group than that of the low and average group (45.9 versus 65 and 66.7%, P00.09), but this difference was only close to statistical significance. In addition, ordinal regression analysis indicated that LH level was the only independent predictor of embryo implantation rates (P00.017). Conclusions In PCOS women, AMH levels on day 3 of the IVF stimulation cycle positively predict ovarian response to gonadotrophins. However, the women with high AMH levels had a significantly decreased IR, which may be due to remarkably increased LH concentrations.Keywords Anti-Müllerian hormone . Assisted reproduction . Polycystic ovary syndrome . Serum AMH Anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance (MIS), is producted specifically by granulose cells of early developing pre-antral and small antral follicles in the ovary, and declines with advancing age. AMH has therefore been proposed as a novel clinical marker of ovarian reserve [1]. Another major reason for the interest in AMH is the fact that serum AMH levels are increased significantly in women with polycystic ovary syndrome (PCOS) when compared with normoovulatory women [2,3].PCOS is the most frequent cause of anovulatory infertility and hyperandrogenism in young women [4]. Women with this syndrome are characterized by an excessive number of small antral follicles (2-3 fold that of normal ovaries) [5]. As an exclusively granulosa cell product, it was initially proposed that the rise in serum AMH in PCOS was a consequence of the increased small antral follicle number in these ovaries [6]. The Capsule In PCOS women, high AMH levels on day 3 of the IVF stimulation cycle predict high ovarian response to gonadotrophins, but low embryo implantation rates.

show abstract

Polycystic ovary syndrome

Cited by 1,345 publications

References 179 publications

Maternal obesity is a potential source of error in mid‐trimester ultrasound estimation of gestational age

Maternal obesity is a potential source of error in mid‐trimester ultrasound estimation of gestational age

Diagnostic Criteria for Polycystic Ovary Syndrome: Pitfalls and Controversies

Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients

Contact Info

Product

Resources

About